Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;80(3):316-329.
doi: 10.1590/0004-282X-ANP-2021-0219.

Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms

Roberta Arb Saba  1   2 , Débora Palma Maia  3 , Francisco Eduardo Costa Cardoso  3 , Vanderci Borges  1 , Luiz Augusto F Andrade  4 , Henrique Ballalai Ferraz  1 , Egberto Reis Barbosa  5 , Carlos Roberto de Mello Rieder  6 , Delson José da Silva  7 , Hsin Fen Chien  5 , Tamine Capato  5 , Ana Lúcia Rosso  8 , Carlos Frederico Souza Lima  9 , José Marcelo Ferreia Bezerra  10 , Denise Nicaretta  11 , Orlando Graziani Povoas Barsottini  1 , Clécio Godeiro-Júnior  12 , Lorena Broseghini Barcelos  1 , Rubens Gisbert Cury  5 , Mariana Spitz  13 , Sônia Maria César Azevedo Silva  1   2 , Marcus Vinicius Della Colletta  14
Affiliations

Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms

Roberta Arb Saba et al. Arq Neuropsiquiatr. 2022 Mar.

Abstract
in English, Portuguese

The treatment of Parkinson's disease (PD) is challenging, especially since it is considered highly individualized. The Brazilian Academy of Neurology has recognized the need to disseminate knowledge about the management of PD treatment, adapting the best evidence to the Brazilian reality. Thus, the main published treatment guidelines were reviewed based on the recommendations of group from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology.

O tratamento da doença de Parkinson (DP) constitui um desafio, especialmente por ser considerado muito individualizado. A Academia Brasileira de Neurologia (ABN) identificou a necessidade de disseminar o conhecimento sobre o manejo do tratamento da DP, adaptando as melhores evidências à realidade brasileira. Assim, foi realizada uma revisão sobre as principais orientações de tratamento publicadas, baseada nas recomendações elaboradas por um grupo de especialistas em transtornos do movimento do departamento científico da ABN.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: RS: has been on the speakers’ bureau/advisory board and/or has acted as a consultant, Teva, Roche, Aché, FQM, and Zambon; DM: has been on the speakers’ bureau/advisory board and/or has acted as a consultant, Roche, UCB, Teva, and Zambon; EB: Roche Laboratory / Support (stay and registration) for participation in the International Congress of Parkinson's Disease and Movement Disorders (NICE, FRANCE SEPTEMBER22-26, 2019); VB: honorary for lecture: FQM, and act as a consultant: Zambon; HBF: Honoraria for lectures and Advisory Board: Apsen, EMS, Roche, Teva, Zambon. Employment: Universidade Federal de São Paulo; CR: has been on the speakers’ bureau/advisory board and/or has acted as a consultant for UCB Biopharma S.A., Teva, Roche, and Medtronic.; CHF: speaker / elaboration of material for continuing medical education at IPSEN; MS: Roche Laboratory / Support (stay and registration) for participation in the International Congress of Parkinson's Disease and Movement Disorders (NICE, FRANCE SEPTEMBER22-26, 2019); DN: speaker / elaboration of material for continuing medical education at FQM, Teva, Zambon, and Sandoz; RC: Rubens G. Cury has received research grant support from FAPESP (Fundação de Amaro à Pesquisa do Estado de São Paulo) and honoraria from Medtronic, Abbott and Boston Scientific for lecturing ; LB: clinical trial investigator sponsored by Medtronic; SMA: speaker / elaboration of material for continuing medical education at Roche; JMFB, LAFA, DJS, ALZR, OGPB, MDC, FC, CFL, COGJ, TC: no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14(2):223–236. doi: 10.1176/jnp.14.2.223. - DOI - PubMed
    1. Gronseth GS, Cox J, Gloss D, Merillat S, Dittman J, Armstrong MJ, et al. 2017 Edition Clinical Practice Guideline Process Manual. Minneapolis(MN): American Academy of Neurology; 2017.
    1. Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson’s disease. Clin Pharmacokinet. 1996;30(6):463–481. doi: 10.2165/00003088-199630060-00004. - DOI - PubMed
    1. Hutton JT, Metman LV, Chase TN, Juncos JL, Koller WC, Pahwa R, et al. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson’s disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord. 2001;16(3):459–463. doi: 10.1002/mds.1085. - DOI - PubMed
    1. Serratrice J, Disdier P, Habib G, Viallet F, Weiller P-J. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev. 2002;10(6):334–336. doi: 10.1097/00045415-200211000-00005. - DOI - PubMed